Novel Anticoagulant Discovery Through Structural Analysis of Coagulation Factors
Nawoo Kim
Saint Paul Preparatory Seoul, Seoul, Republic of Korea
Publication date: May 31, 2025
Saint Paul Preparatory Seoul, Seoul, Republic of Korea
Publication date: May 31, 2025
DOI: http://doi.org/10.34614/JIYRC2025I18
ABSTRACT
Coagulation involves a complex network of coagulation factors that work together to form blood clots, essential for stopping bleeding. However, excessive or misplaced clotting can cause thrombosis, blocking veins, arteries, or organs, leading to severe conditions like Venous Thromboembolism or Atrial Fibrillation, making anticoagulants vital for treatment. This paper focuses on investigating coagulation factors X (FX) and XI (FXI) to identify new approaches for developing anticoagulants. Delving into the structural biology of these coagulation factor proteins, the possibility of further developing and using FXI as a major anticoagulant drug was confirmed. Compared to FX, FXI’s dimeric protein structure and inhibition site location offers advantages in rapid anticoagulation, inhibiting the coagulation cascade quickly. By analyzing the molecular structures of these proteins to discover new anticoagulation strategies, novel anticoagulants may provide safer and more effective alternatives to current therapies, offering improved management of thrombolytic conditions while minimizing the risk of adverse effects.
Coagulation involves a complex network of coagulation factors that work together to form blood clots, essential for stopping bleeding. However, excessive or misplaced clotting can cause thrombosis, blocking veins, arteries, or organs, leading to severe conditions like Venous Thromboembolism or Atrial Fibrillation, making anticoagulants vital for treatment. This paper focuses on investigating coagulation factors X (FX) and XI (FXI) to identify new approaches for developing anticoagulants. Delving into the structural biology of these coagulation factor proteins, the possibility of further developing and using FXI as a major anticoagulant drug was confirmed. Compared to FX, FXI’s dimeric protein structure and inhibition site location offers advantages in rapid anticoagulation, inhibiting the coagulation cascade quickly. By analyzing the molecular structures of these proteins to discover new anticoagulation strategies, novel anticoagulants may provide safer and more effective alternatives to current therapies, offering improved management of thrombolytic conditions while minimizing the risk of adverse effects.
